Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2575995 | The American Journal of Geriatric Pharmacotherapy | 2008 | 9 Pages |
Abstract
Conclusions: Compared with the IPR cohort, the FSC 500/50 cohort was 45% less likely to have a COPD-related exacerbation event and had similar medical costs. FSC 500/50 was a more effective initial maintenance therapy than IPR for this Medicare population, and, despite the $260 increase in COPD-related pharmacy costs, there was no significant difference in COPD-related medical costs.
Related Topics
Health Sciences
Medicine and Dentistry
Geriatrics and Gerontology
Authors
Christopher M. PhD, Manabu PhD, MPH, Anand PhD, MBA, Linda PhD,